The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2006California Parkinson's Disease Registry Pilot Project
Much remains to be elucidated about causes of Parkinson’s disease, a progressive neurodegenerative condition that affects at least 1,000,000 people in the United States. For example, little detailed...
-
Community Fast Track, 2002Proactive action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a pre-clinical model model of Parkinson's disease
Recently, in mouse studies the peroxisome proliferator-activated receptor-g (PPARg) agonist pioglitazone was shown to be effective in blocking the substantia nigra (SN) cell loss induced by MPTP in a...
-
MJFF Research Grant, 2005Nebraska Parkinson's Disease Registry
The American Parkinson Disease Association (APDA) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) are co-funding the Nebraska Parkinson's Disease Registry with a three-year...
-
LEAPS, 2005Michael J. Fox Foundation Validation Study
The role of genetics in PD continues to be a major focus in the field and much of what we know about possible underlying mechanisms of PD cause and pathogenesis has come through studies of genes (e.g...
-
Rapid Response Innovation Awards, 2007Development of a Cellular System to Screen for Small Molecules that Upregulate the hVMAT2 Promoter Activity
Objective/Rationale:
We will develop an essential cellular system as a platform for future high throughput screen (HTS) for novel small molecules that increase levels of the human vesicular monoamine... -
Rapid Response Innovation Awards, 2007Development and Initial Characterization of an Enzyme-linked Immunosorbent Assay for the Candidate PD Risk Marker ST13
Objective/Rationale:
Clinical signs of Parkinson’s disease develop only after the death of around 70 percent of vulnerable dopaminergic neurons. Laboratory tests for PD are not currently available...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.